A major women’s health condition affecting nearly 170 million women worldwide is set to receive a new name as global researchers and medical organizations aim to improve diagnosis, awareness, and patient care. The condition currently known as Polycystic Ovary Syndrome will now be referred to as Polyendocrine Metabolic Ovarian Syndrome (PMOS), according to researchers speaking at the European Congress of Endocrinology in Prague. The proposed name change was announced alongside the publication of a report in The Lancet and additional research findings published in JAMA Internal Medicine.
Why Researchers Want to Rename PCOS
Experts say the current term “polycystic ovary syndrome” often creates confusion because many patients do not actually have ovarian cysts. According to Terhi Piltonen of the University of Oulu, the name has historically caused both patients and healthcare professionals to associate the disorder mainly with ovarian cysts, leading to delays in diagnosis and fragmented treatment approaches.
Researchers explained that women with the condition typically have an excess of antral follicles — small fluid-filled sacs containing immature eggs — rather than true ovarian cysts. By introducing the term PMOS, experts aim to better reflect the disorder’s broader hormonal, metabolic, reproductive, and psychological impacts.
PMOS Reflects the Full Spectrum of Symptoms
The newly proposed name highlights the condition’s complex endocrine and metabolic nature, which extends far beyond reproductive health.
Common symptoms associated with PMOS include:
*Irregular or absent menstrual cycles
*Infertility and pregnancy complications
*Excess facial and body hair growth
*Acne and hormonal imbalance
*Anxiety and depression
*Weight gain and obesity
*Insulin resistance and diabetes
*Increased cardiovascular disease risk
Researchers believe the updated terminology will help improve patient understanding, encourage earlier diagnosis, and support more comprehensive treatment strategies.
Global Consultation Led to Name Change
The decision to adopt the term PMOS followed an extensive international consultation process led by several research groups and the Androgen Excess and PCOS Society.
The consensus was based on:
*More than 14,000 survey responses from patients and healthcare professionals worldwide
*Two international workshops
*Input from 56 academic, clinical, and patient advocacy organizations
The initiative reflects growing efforts within the medical community to modernize terminology and improve communication around women’s health conditions.
No Cure Yet, But Symptoms Can Be Managed
Although PMOS currently has no permanent cure, experts emphasize that its symptoms can be effectively managed through medications, lifestyle modifications, diet, and exercise. According to the Endocrine Society, early diagnosis and comprehensive treatment can significantly improve quality of life and reduce long-term health risks associated with the condition.
Transition to PMOS Already Underway
Researchers stated that plans are already in motion to gradually transition from PCOS to PMOS over the next three years.
The rollout will include:
*Integration into healthcare systems
*Updates to clinical guidelines
*Professional medical training
*Inclusion in disease classification systems
As reported by reuters.com, experts believe the new terminology could play an important role in reducing stigma, improving healthcare communication, and strengthening women’s reproductive and metabolic healthcare globally.